Literature DB >> 526002

Disk diffusion testing of susceptibility of Mycobacterium fortuitum and Mycobacterium chelonei to antibacterial agents.

R J Wallace, J R Dalovisio, G A Pankey.   

Abstract

Although recent studies have suggested that some antibacterial agents have good activity against the rapidly growing mycobacteria Mycobacterium fortuitum and Mycobacterium chelonei, an easily applicable method for susceptibility testing of clinical isolates is not yet available. We evaluated a disk diffusion method with Mueller-Hinton agar and 48-h readings with 59 strains of M. fortuitum and 11 strains of M. chelonei and compared the results to agar dilution susceptibilities for nine antimicrobial agents. All isolates were susceptible to 16 micrograms of amikacin or kanamycin per ml with minimum zone diameters of 14 and 18 mm, respectively. Amikacin inhibited 100% of isolates of M. fortuitum at 2 micrograms/ml, whereas 10 of 11 (91%) of M. chelonei strains had minimum inhibitory concentrations of 4.0 micrograms/ml or greater. Doxycycline and minocycline had almost identical activities, inhibiting 44% of strains at 4.0 micrograms/ml, and both allowed easy differentiation between susceptible and resistant strains by disk diffusion. Although most isolates of M. chelonei grew better on 7H10 agar, this media gave two- to eight-fold higher minimum inhibitory concentrations than were obtained with Mueller-Hinton agar. Disk diffusion susceptibility testing appears to be a simple and reliable means of predicting susceptibility results for M. fortuitum and most isolates of M. chelonei by the agar dilution method.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 526002      PMCID: PMC352914          DOI: 10.1128/AAC.16.5.611

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  6 in total

1.  Susceptibility of organisms in the Mycobacterium fortuitum complex to antituberculous and other antimicrobial agents.

Authors:  W E Sanders; E C Hartwig; N J Schneider; R Cacciatore; H Valdez
Journal:  Antimicrob Agents Chemother       Date:  1977-08       Impact factor: 5.191

2.  Clinical significance of Mycobacterium fortuitum infections in pulmonary disease.

Authors:  R J Awe; P R Gangadharam; D E Jenkins
Journal:  Am Rev Respir Dis       Date:  1973-11

3.  In-vitro activity of erythromycin against atypical mycobacteria.

Authors:  A Molavi; L Weinstein
Journal:  J Infect Dis       Date:  1971-02       Impact factor: 5.226

4.  Activity of amikacin, erythromycin and doxycyline against Mycobacterium chelonei and Mycobacterium fortuitum.

Authors:  J A Garcia-Rodriguez; F Martin-Luengo
Journal:  Tubercle       Date:  1978-12

5.  Antimicrobial susceptibility testing of Mycobacterium fortuitum complex.

Authors:  D F Welch; M T Kelly
Journal:  Antimicrob Agents Chemother       Date:  1979-06       Impact factor: 5.191

6.  In vitro susceptiiblity of Mycobacterium fortuitum and Mycobacterium chelonei to amikacin.

Authors:  J R Dalovisio; G A Pankey
Journal:  J Infect Dis       Date:  1978-03       Impact factor: 5.226

  6 in total
  26 in total

Review 1.  Antimicrobial susceptibility testing, drug resistance mechanisms, and therapy of infections with nontuberculous mycobacteria.

Authors:  Barbara A Brown-Elliott; Kevin A Nash; Richard J Wallace
Journal:  Clin Microbiol Rev       Date:  2012-07       Impact factor: 26.132

2.  Bacteremia caused by Mycobacterium neoaurum.

Authors:  M B Davison; J G McCormack; Z M Blacklock; D J Dawson; M H Tilse; F B Crimmins
Journal:  J Clin Microbiol       Date:  1988-04       Impact factor: 5.948

3.  Mycobacterium fortuitum bacteremia in an immunocompromised patient with a long-term venous catheter.

Authors:  A Moreno; M Llanos; A González; N Batista
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-05       Impact factor: 3.267

4.  Evaluation of Etest for susceptibility testing of rapidly growing mycobacteria.

Authors:  J R Biehle; S J Cavalieri; M A Saubolle; L J Getsinger
Journal:  J Clin Microbiol       Date:  1995-07       Impact factor: 5.948

5.  Susceptibilities of Mycobacterium fortuitum biovariant fortuitum and the unnamed third biovariant complex to heavy-metal salts.

Authors:  R J Wallace; L C Steele; G D Forrester; J M Swenson; S I Hull
Journal:  Antimicrob Agents Chemother       Date:  1984-10       Impact factor: 5.191

6.  Disk diffusion testing with polymyxin and amikacin for differentiation of Mycobacterium fortuitum and Mycobacterium chelonei.

Authors:  R J Wallace; J M Swenson; V A Silcox; R C Good
Journal:  J Clin Microbiol       Date:  1982-12       Impact factor: 5.948

7.  In vitro activities of norfloxacin and ciprofloxacin against Mycobacterium tuberculosis, M. avium complex, M. chelonei, M. fortuitum, and M. kansasii.

Authors:  J D Gay; D R DeYoung; G D Roberts
Journal:  Antimicrob Agents Chemother       Date:  1984-07       Impact factor: 5.191

8.  Agar disk elution method for susceptibility testing of Mycobacterium marinum and Mycobacterium fortuitum complex to sulfonamides and antibiotics.

Authors:  M S Stone; R J Wallace; J M Swenson; C Thornsberry; L A Christensen
Journal:  Antimicrob Agents Chemother       Date:  1983-10       Impact factor: 5.191

9.  Antimicrobial susceptibility of five subgroups of Mycobacterium fortuitum and Mycobacterium chelonae.

Authors:  J M Swenson; R J Wallace; V A Silcox; C Thornsberry
Journal:  Antimicrob Agents Chemother       Date:  1985-12       Impact factor: 5.191

10.  Ability of ciprofloxacin but not pipemidic acid to differentiate all three biovariants of Mycobacterium fortuitum from Mycobacterium chelonae.

Authors:  L C Steele; R J Wallace
Journal:  J Clin Microbiol       Date:  1987-02       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.